Powder-in-Bottle Formulation of SU011248. Enabling Rapid Progression into Human Clinical Trials

Drug Development and Industrial Pharmacy

Volumn 30, Issue 1, 2004, Pages 19-25

  Sistla, Anand ^a,b   Sunga, Alan ^a   Phung, Kenneth ^a   Koparkar, Arun ^a   Shenoy, Narmada ^a  

^a SUGEN INC   (United States)

^b PFIZER INC   (United States)

Author keywords

Constitution; Powder in bottle formulation; SU011248

Indexed keywords

RECEPTOR TYROSINE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG;

APPLE JUICE; AQUEOUS SOLUTION; ARTICLE; CLINICAL TRIAL; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PARTICLE SIZE; PHYSICAL CHEMISTRY; SUSPENSION; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS; DRUG STABILITY; DRUG STORAGE; HUMANS; HYDROGEN-ION CONCENTRATION; INDOLES; PARTICLE SIZE; POWDERS; PYRROLES; SOLUBILITY; TEMPERATURE;

EID: 1242321027     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120027507     Document Type: Article

References (8)

1. Mendel, D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, G.; Schreck, R.E.; Abrams, T.J.; Ngai, T.J.; Lee, L.B.; Murray, L.J.; Carver, J.; Chan, E.; Moss, K.G.; Haznedar, J.O.; Sukbuntherng, J.; Blake, R.A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J.M. In vivo anti-tumor activity of SU011248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9 (1), 327-337.
2. Allen, L.V., Jr.; Erickson, M.A., III. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am. J. Health-Syst. Pharm. 1998, 55 (18), 1915-1920.
3. Allen, L.V., Jr.; Erickson, M.A. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids. Am. J. Health-Syst. Pharm. 1998, 55 (17), 1804-1809.
4. Allen, L.V., Jr.; Erickson, M.A., III. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Am. J. Health-Syst. Pharm. 1996, 53 (17), 2073-2078.
5. Boonme, P.; Phadoongsombut, N.; Phoomborplub, P.; Viriyasom, S. Stability of extemporaneous norfloxacin suspension. Drug Devel. Ind. Pharm. 2000, 26 (7), 777-779.
6. Aubry, A.F.; Sebastian, D.; Hobson, T.; Xu, J.Q.; Rabel, S.; Xie, M.; Gray, V. In use testing of extemporaneously prepared suspensions of second generation non-nucleoside reversed transcripts inhibitors in support of Phase I clinical studies. J. Pharm. Biomed. Anal. 2000, 23 (200), 535-542.
7. Ho, P.-C.; Ghose, K.; Saville, D.; Wanwimolruk, S. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur. J. Clin. Pharmacol. 2000, 56 (9-10), 693-698.
8. Takanaga, H.; Ohnishi, A.; Matsuo, H.; Murakami, H.; Sata, H.; Kuroda, K.; Urae, A.; Higuchi, S.; Sawada, Y. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br. J. Clin. Pharmacol. 2000, 49 (1), 49-58.